BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Rigel Pharmaceuticals, Inc. 

1180 Veterans Boulevard

South San Francisco  California  94080  U.S.A.
Phone: 650-624-1100 Fax: 650-624-1101


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Rigel's. Rigel's mission is to become a source of novel, small-molecule drugs to address large, unmet medical needs. We have initiated four development programs: asthma/allergy, hepatitis C, rheumatoid arthritis and oncology. Our first two product candidates, R112 for allergic rhinitis and R803 for hepatitis C, are in clinical testing. We expect to begin a clinical trial of R406 for the treatment of rheumatoid arthritis by the end of 2004, to be followed by initiation of clinical trials with additional product candidates for indications in oncology and asthma. Our approach to drug discovery is based on advanced, proprietary techniques that allow us to identify targets with a demonstrable role in a disease pathway and to screen efficiently for those targets that are likely to be amenable to drug modulation. We believe that this approach to drug discovery will enable us to commence clinical trials with one to two lead compounds each year. Our research efforts are focused in the areas of immunology/inflammation, virology and oncology.

Last Updated: 10-18-04


 Key Statistics


Email: communications@rigel.com
Ownership: Public

Web Site: Rigel Pharmaceuticals, Inc.
Employees: 135
Symbol: RIGL
 



Industry
Biotechnology

Segment
Drug Discovery





 Company News
Rigel Pharmaceuticals, Inc. (RIGL) Chairman And CEO James Gower Retires 11/24/2014 10:23:14 AM
Rigel Pharmaceuticals, Inc. (RIGL) Announces Third Quarter 2014 Financial Results 11/4/2014 8:53:12 AM
Rigel Pharmaceuticals, Inc. (RIGL) Experimental Eye Drug R348 Fails Mid-Stage Study 8/13/2014 6:20:36 AM
Rigel Pharmaceuticals, Inc. (RIGL) Announces Second Quarter 2014 Financial Results 8/5/2014 7:54:08 AM
Rigel Pharmaceuticals, Inc. (RIGL) Initiates Phase 3 Studies Of Fostamatinib In ITP 7/16/2014 9:16:55 AM
Rigel Pharmaceuticals, Inc. (RIGL) To Present At Jefferies and Co. 2014 Global Healthcare Conference 5/29/2014 6:53:32 AM
Rigel Pharmaceuticals, Inc. (RIGL) Announces First Quarter 2014 Financial Results 5/7/2014 7:01:33 AM
Rigel Pharmaceuticals, Inc. (RIGL) Announces Webcast Of Investor Day On May 6, 2014 4/30/2014 7:30:23 AM
Rigel Pharmaceuticals, Inc. (RIGL) Announces Participation At Two Investor Conferences 2/27/2014 6:53:13 AM
Rigel Pharmaceuticals, Inc. (RIGL) Announces Participation At Two Investor Conferences 2/6/2014 6:33:41 AM
12345678910...